Compare TransMedics Group Inc (TMDX) vs Twilio Inc (TWLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs Twilio Inc — how do they compare? TransMedics Group Inc trades at $87.42 (market cap $3.10B), while Twilio Inc trades at $245.38 (market cap $39.31B). The key difference: Twilio Inc is far larger — about 12.7× TransMedics Group Inc's market cap, and Twilio Inc is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| TMDX | TWLO | |
|---|---|---|
Market Cap | $3.10B | $39.31B |
Sector | Technology | Technology |
52-Week High | $150.42 | $255.95 |
52-Week Low | $61.99 | $95.23 |
Enterprise Value | $3.49B | $37.72B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TransMedics Group (TMDX) trades at $87.42, down 1.12% on the day, with a bullish technical outlook from moving averages but bearish oscillators signaling potential overbought conditions. The company reported mixed Q2 2026 results, missing earnings estimates with EPS of $0.44 versus $0.50 expected, while revenue growth remains robust. Recent news highlights an ongoing investigation into fiduciary duties by directors, adding uncertainty.
The stock presents a cautious opportunity with strong analyst support (69% buy ratings) and a consensus price target of $99.57, implying upside, but risks include earnings volatility, margin pressures, and legal scrutiny. Fundamentals show solid profitability with a 22.69% net margin, though valuation multiples like P/E of 23.15 suggest premium pricing relative to historical norms.
Twilio (TWLO) trades at $247.10, down 1.18% on the day, but remains near its 52-week high after a strong rally driven by Q2 2026 earnings beats and raised guidance. The stock shows bullish technical signals with support at $246 and resistance at $259. Revenue growth accelerated to 22% year-over-year in Q2, with net income turning positive in 2025 after years of losses, reflecting improved profitability and cash flow generation.
Outlook is positive with Wall Street consensus Buy rating and $266.31 price target, though high valuation multiples (P/E 35.35) and overbought RSI levels suggest near-term consolidation risk. Key opportunities include AI-driven growth and expanding free cash flow margins, while risks involve competitive pressures and execution on guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About Twilio Inc
Twilio Inc. is a cloud-based communication platform-as-a-service company offering communication building blocks that allow for a fully customized customer engagement experience spanning voice, video, chat, and SMS messaging. It does this through various application programming interfaces, or APIs, and prebuilt solution applications aimed at improving customer engagement. The company leverages its Super Network, a global network of carrier relationships, to facilitate high-speed, cost-effective communication.
Read more on TWLO →
